Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Mar;35(3):451–457. doi: 10.1128/aac.35.3.451

Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.

P Van der Auwera 1, M Aoun 1, F Meunier 1
PMCID: PMC245031  PMID: 1828134

Abstract

Seventy-four immunocompromised patients with severe infection due to gram-positive organisms were randomized to receive either vancomycin or teicoplanin. Extensive cancer was present in 71 patients, of whom 47 died within a month. The types of infections were 46 bacteremias (39 associated with central catheters), 24 skin and soft tissue infections (3 with bacteremia), and 7 others (mainly bronchopneumonia). The most frequent pathogen was Staphylococcus epidermidis, followed by Staphylococcus aureus. Microbiological eradication was obtained in 23 of 35 evaluable patients treated with vancomycin (65.7%) and 28 of 36 patients treated with teicoplanin (77.8%) (P = 0.4). Clinical cure and improvement were obtained in 26 of 35 patients (74.3%) and 27 of 36 patients (75.0%), respectively. No significant side effects were observed with teicoplanin, in contrast to reversible increases in serum creatinine (three patients) and skin rashes (four patients) with vancomycin. Superinfection was observed in five patients treated with vancomycin and two patients treated with teicoplanin. No relation was found between peak concentration in serum (at steady state) or bactericidal titers and outcome.

Full text

PDF
451

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bibler M. R., Frame P. T., Hagler D. N., Bode R. B., Staneck J. L., Thamlikitkul V., Harris J. E., Haregewoin A., Bullock W. E., Jr Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections. Antimicrob Agents Chemother. 1987 Feb;31(2):207–212. doi: 10.1128/aac.31.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Calain P., Krause K. H., Vaudaux P., Auckenthaler R., Lew D., Waldvogel F., Hirschel B. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987 Feb;155(2):187–191. doi: 10.1093/infdis/155.2.187. [DOI] [PubMed] [Google Scholar]
  3. Craven D. E., Kollisch N. R., Hsieh C. R., Connolly M. G., Jr, McCabe W. R. Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus. J Infect Dis. 1983 Jan;147(1):137–143. doi: 10.1093/infdis/147.1.137. [DOI] [PubMed] [Google Scholar]
  4. Geraci J. E., Wilson W. R. Vancomycin therapy for infective endocarditis. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S250–S258. [PubMed] [Google Scholar]
  5. Glupczynski Y., Lagast H., Van der Auwera P., Thys J. P., Crokaert F., Yourassowsky E., Meunier-Carpentier F., Klastersky J., Kains J. P., Serruys-Schoutens E. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 1986 Jan;29(1):52–57. doi: 10.1128/aac.29.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goldstein F. W., Coutrot A., Sieffer A., Acar J. F. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother. 1990 May;34(5):899–900. doi: 10.1128/aac.34.5.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hiemenz J., Skelton J., Pizzo P. A. Perspective on the management of catheter-related infections in cancer patients. Pediatr Infect Dis. 1986 Jan-Feb;5(1):6–11. doi: 10.1097/00006454-198601000-00002. [DOI] [PubMed] [Google Scholar]
  8. Klastersky J., Coppens L., van der Auwera P., Meunier-Carpentier F. Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother. 1983 Apr;11(4):361–367. doi: 10.1093/jac/11.4.361. [DOI] [PubMed] [Google Scholar]
  9. Leclercq R., Derlot E., Weber M., Duval J., Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1989 Jan;33(1):10–15. doi: 10.1128/aac.33.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Leport C., Perronne C., Massip P., Canton P., Leclercq P., Bernard E., Lutun P., Garaud J. J., Vilde J. L. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob Agents Chemother. 1989 Jun;33(6):871–876. doi: 10.1128/aac.33.6.871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Martino P., Venditti M., Micozzi A., Brandimarte C., Gentile G., Santini C., Serra P. Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother. 1989 Aug;33(8):1329–1334. doi: 10.1128/aac.33.8.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maugein J., Pellegrin J. L., Brossard G., Fourche J., Leng B., Reiffers J. In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients. Antimicrob Agents Chemother. 1990 May;34(5):901–903. doi: 10.1128/aac.34.5.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pauluzzi S., Del Favero A., Menichetti F., Baratta E., Moretti V. M., Di Filippo P., Pasticci M. B., Guerciolini R., Patoia L., Frongillo R. F. Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study. J Antimicrob Chemother. 1987 Sep;20(3):431–438. doi: 10.1093/jac/20.3.431. [DOI] [PubMed] [Google Scholar]
  14. Reller L. B., Stratton C. W. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis. 1977 Aug;136(2):196–204. doi: 10.1093/infdis/136.2.196. [DOI] [PubMed] [Google Scholar]
  15. Ringdén O., Heimdahl A., Lönnqvist B., Malmborg A. S., Wilczek H. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet. 1984 Mar 31;1(8379):744–744. doi: 10.1016/s0140-6736(84)92259-1. [DOI] [PubMed] [Google Scholar]
  16. Ruoff K. L., Kuritzkes D. R., Wolfson J. S., Ferraro M. J. Vancomycin-resistant gram-positive bacteria isolated from human sources. J Clin Microbiol. 1988 Oct;26(10):2064–2068. doi: 10.1128/jcm.26.10.2064-2068.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Small P. M., Chambers H. F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990 Jun;34(6):1227–1231. doi: 10.1128/aac.34.6.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Smith S. R., Cheesbrough J., Spearing R., Davies J. M. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother. 1989 Aug;33(8):1193–1197. doi: 10.1128/aac.33.8.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Van Laethem Y., Hermans P., De Wit S., Goosens H., Clumeck N. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):81–87. doi: 10.1093/jac/21.suppl_a.81. [DOI] [PubMed] [Google Scholar]
  20. Van der Auwera P. Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob Agents Chemother. 1989 Oct;33(10):1783–1790. doi: 10.1128/aac.33.10.1783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Van der Auwera P., Klastersky J. Bactericidal activity and killing rate of serum in volunteers receiving teicoplanin alone or in combination with oral or intravenous rifampin. Antimicrob Agents Chemother. 1987 Jul;31(7):1002–1005. doi: 10.1128/aac.31.7.1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Van der Auwera P., Klastersky J. Bactericidal activity and killing rate of serum in volunteers receiving vancomycin or teicoplanin with and without amikacin given intravenously. J Antimicrob Chemother. 1987 May;19(5):623–635. doi: 10.1093/jac/19.5.623. [DOI] [PubMed] [Google Scholar]
  23. Van der Auwera P., Klastersky J., Thys J. P., Meunier-Carpentier F., Legrand J. C. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother. 1985 Oct;28(4):467–472. doi: 10.1128/aac.28.4.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Verbist L., Tjandramaga B., Hendrickx B., Van Hecken A., Van Melle P., Verbesselt R., Verhaegen J., De Schepper P. J. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother. 1984 Dec;26(6):881–886. doi: 10.1128/aac.26.6.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Viscoli C., Van der Auwera P., Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother. 1988 Apr;21 (Suppl 100):149–156. doi: 10.1093/jac/21.suppl_c.149. [DOI] [PubMed] [Google Scholar]
  26. Webster A., Russell S. J., Souhami R. L., Richards J. D., Goldstone A. H., Grüneberg R. N. Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients. J Hosp Infect. 1987 Jul;10(1):77–82. doi: 10.1016/0195-6701(87)90036-3. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES